Softomotive: Empowering Citizen Developers in Japan, South Korea and China Master RPA
Softomotive, the fastest growing Robotic Process Automation (RPA) provider trusted by over 9000 clients globally, announces the localization of its comprehensive free online RPA training to meet the increasing demand of Softomotive’s RPA solutions across 3 new markets: Japan, South Korea and Greater China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191215005029/en/
Softomotive expands Free online RPA training to 3 new markets: Japan, South Korea and Greater China. (Photo: Business Wire)
Together with the English version, Softomotive’s courses in RPA are now available in Japanese, Mandarin and Korean, with more local versions to come. WinAutomation users in Asia can now benefit from a more tailored experience and master RPA skills through the fully localized curriculum including the on-demand video courses, fact-sheets and quizzes.
“With the localized version of Softomotive’s RPA courses we are able to help even more developers and professionals master RPA skills covering Attended and UnAttended Automation.” says Marios Stavropoulos, Co-Founder and CEO for Softomotive. “By providing WinAutomation courses in Korean, Japanese, and Mandarin we are enabling the growth and adoption of RPA, making it much easier for organizations in those regions to train their employees as they seek to deploy and implement RPA”.
Continuing on its mission to improve the employability quotient of professionals and developers, Softomotive began working with channel partners who have both domain and linguistic expertise to improve the quality of the translations.
Several of our customers in South Korea and Japan also commented on the value of having localized courses on WinAutomation. One said that having Korean courses available is extremely helpful in educating employees and helping citizen developers start creating automations for the business much faster.
The official reveal of the localized courses was done in front of clients and partners in a series of events and meetings Seoul (South Korea), Tokyo (Japan) and Bengaluru (India). During these events, Softomotive’s leadership highlighted the role of Asia-Pacific region as one where RPA adoption is expected to see tremendous growth. The successful events and meetings served as a great platform to showcase how Softomotive’s People1st Approach to RPA, a bottom-up approach giving the power of automation to employees, is enabling businesses locally in South Korea, Japan and Greater China respond to the pressures of reduced labor productivity, following the recent regulations on working hours and work styles.
With the latest updates to the Softomotive Academy, learners from Japan, South Korea and China can obtain a Certification and Diploma in Robotic Process Automation.
Entering the world of the Softomotive Academy is the first step to gaining credibility.
The online RPA learning portal provides an intuitive web-based interface that is accessible from any device (including mobile). Professionals can enroll and discover a rich catalogue of video-based RPA tutorials that support on-demand and self-paced learning on Attended and Unattended Automation.
Automation knowledge is fast becoming an essential skill set in the labor market.
The RPA Academy offers easy-to-follow individual courses helping learners to master RPA skills covering Attended and Unattended automation. Training ranges from a solid foundation on Robotic Desktop Automation (RDA) and enterprise RPA, to the development of complex process automation via scripting, and the advanced management and monitoring of software robots.
Receiving an Accreditation in Softomotive’s Process Automation solutions, learners become part of a global network of thousands of professionals already helping their respective organizations accelerate their digitization efforts. A Diploma in RPA enables professionals and developers stay ahead of the rest in this exciting industry. Learners can watch RPA courses at any time tailored for specific roles or can fully customize their learning experience based on their personal learning objectives.
Visit the Softomotive Academy to see the RPA courses in Japanese, Korean and Mandarin.
Softomotive is one of the leading worldwide providers of Robotic Process Automation (RPA) solutions, trusted by more than 9,000 companies worldwide. Both attended and unattended RPA are delivered through powerful, robust RPA technology, from desktop installation to server-based software which is quick to deploy, easy to use and provides the best value for money
WinAutomation is the world’s best Robotic desktop automation (RDA) tool and provides a powerful, robust and easy to use Windows-based platform for building software robots.
ProcessRobot is a leading enterprise RPA platform, including enterprise grade security and controls, with links to best-of-breed AI technologies.
#ProcessRobot #Softomotive #WinAutomation
For more information:
Softomotive Press Office
Tel: +44 207 048 2000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom